Skip to main content

Advertisement

SpringerLink
Log in

Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The objective of this study was to compare health-related quality of life (HRQOL) between diffuse large B cell lymphoma (DLBCL) survivors of different age categories (18–59/60–75/76–85 years) and to compare their HRQOL with an age- and sex-matched normative population. The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with DLBCL from 1999 to 2010. Patients (n = 363) were invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, and 307 survivors responded (85 %). Data from an age- and sex-matched normative population (n = 596) were used for comparison. DLBCL survivors aged 18–59 years scored better on physical functioning, quality of life, appetite loss and constipation than survivors of 76–85 years old (all p < 0.05). Financial problems more often occurred in survivors aged 18–59 years compared to survivors of 76–85 years old (p < 0.01). Compared to the normative population, DLBCL survivors aged 18–59 years showed worse scores on cognitive and social functioning and on dyspnea and financial problems (p < 0.01, large- and medium-size effects). In survivors of the other age categories, only differences with trivial or small-size effects were found. Although younger DLBCL survivors have better HRQOL than older survivors, the differences found between younger survivors and normative population were the largest. This suggests that having DLBCL has a greater impact on younger than older survivors and that the worse HRQOL observed in older DLBCL survivors in comparison with younger survivors is caused mostly by age itself and not by the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. KWF kankerbestrijding, Signaleringcommissie Kanker. Kanker in Nederland tot 2020. Trends and Prognoses (in Dutch). http://www.kwfkankerbestrijding.nl

  2. US National Coalition for Cancer Survivorship (2013) http://www.canceradvocacy.org. Accessed 29 May 2013

  3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242

    Article  PubMed  CAS  Google Scholar 

  4. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117–4126

    Article  PubMed  CAS  Google Scholar 

  5. van de Schans SA, Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23(5):1280–1286

    Article  PubMed  Google Scholar 

  6. Peters FP, Lalisang RI, Fickers MM, Erdkamp FL, Wils JA, Houben SG et al (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 80(3):155–159

    Article  PubMed  CAS  Google Scholar 

  7. Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C et al (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19(4):774–779

    Article  PubMed  CAS  Google Scholar 

  8. Peters FP, Fickers MM, Erdkamp FL, Wals J, Wils JA, Schouten HC (2001) The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol 80(7):406–410

    Article  PubMed  CAS  Google Scholar 

  9. Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D et al (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137(7):1079–1084

    Article  PubMed  Google Scholar 

  10. Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C et al (2011) Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leuk Lymphoma 52(7):1239–1248

    Article  PubMed  Google Scholar 

  11. Smith SK, Zimmerman S, Williams CS, Zebrack BJ (2009) Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115(14):3312–3323

    Article  PubMed Central  PubMed  Google Scholar 

  12. Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S, Cavallin-Stahl E (2001) Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol 18(1):85–94

    Article  PubMed  CAS  Google Scholar 

  13. Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M et al (2004) Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica 89(8):973–978

    PubMed  Google Scholar 

  14. Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA (2010) The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psychooncology 19(12):1259–1267

    Article  PubMed Central  PubMed  Google Scholar 

  15. Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML et al (2007) Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 109(8):1659–1667

    Article  PubMed  Google Scholar 

  16. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P (2005) Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 75(2):116–123

    Article  PubMed  CAS  Google Scholar 

  17. Persson L, Larsson G, Ohlsson O, Hallberg IR (2001) Acute leukaemia or highly malignant lymphoma patients' quality of life over two years: a pilot study. Eur J Cancer Care (Engl) 10(1):36–47

    Article  CAS  Google Scholar 

  18. Geffen DB, Blaustein A, Amir MC, Cohen Y (2003) Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel. Leuk Lymphoma 44(11):1925–1929

    Article  PubMed  Google Scholar 

  19. Fritz APC, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organisation, Geneva

    Google Scholar 

  20. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194

    Article  PubMed  Google Scholar 

  21. van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47(5):667–675

    Article  PubMed  Google Scholar 

  22. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376

    Article  PubMed  CAS  Google Scholar 

  23. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163

    Article  PubMed  Google Scholar 

  24. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96

    Article  PubMed  Google Scholar 

  25. Hall AE, Boyes AW, Bowman J, Walsh RA, James EL, Girgis A (2012) Young adult cancer survivors' psychosocial well-being: a cross-sectional study assessing quality of life, unmet needs, and health behaviors. Support Care Cancer 20(6):1333–1341

    Article  PubMed  Google Scholar 

  26. Bifulco G, De Rosa N, Tornesello ML, Piccoli R, Bertrando A, Lavitola G et al (2012) Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. Gynecol Oncol 124(3):444–451

    Article  PubMed  CAS  Google Scholar 

  27. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356

    Article  PubMed  Google Scholar 

  28. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9):1905–1913

    Article  PubMed  CAS  Google Scholar 

  29. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13(9):1387–1397

    Article  PubMed  CAS  Google Scholar 

  30. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292–2299

    Article  PubMed  CAS  Google Scholar 

  31. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104(11):2499–2507

    Article  PubMed Central  PubMed  Google Scholar 

  32. Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM et al (2013) Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer 119(3):672–680

    Article  PubMed Central  PubMed  Google Scholar 

  33. Zebrack BJ, Yi J, Petersen L, Ganz PA (2008) The impact of cancer and quality of life for long-term survivors. Psychooncology 17(9):891–900

    Article  PubMed  Google Scholar 

  34. Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M (2010) Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma 51(11):2012–2020

    Article  PubMed  CAS  Google Scholar 

  35. Mols F, Thong MS, Vissers P, Nijsten T, van de Poll-Franse LV (2012) Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer 48(13):2037–2042

    Article  PubMed  Google Scholar 

  36. Mols F, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Aaronson NK, Lybeert ML et al (2006) Better quality of life among 10–15 year survivors of Hodgkin's lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 42(16):2794–2801

    Article  PubMed  Google Scholar 

  37. Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV (2009) Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology 18(12):1252–1260

    Article  PubMed  Google Scholar 

  38. Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U et al (2012) Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma 53(3):394–399

    Article  PubMed  CAS  Google Scholar 

  39. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(19):3159–3165

    Article  PubMed  CAS  Google Scholar 

  40. Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K et al (2012) Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol 158(4):481–488

    Article  PubMed  CAS  Google Scholar 

  41. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH et al (2012) The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 91(9):1383–1391

    Article  PubMed  Google Scholar 

  42. Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD (2012) Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer 118(24):6079–6088

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank all patients and their doctors for their participation in the study. Special thanks go to Dr. M. van Bommel for independent advice and answering questions of patients. The following hospitals provided cooperation: Catharina Hospital, Eindhoven; Jeroen Bosch Hospital, 's-Hertogenbosch; Maxima Medical Centre, Eindhoven and Veldhoven; Sint Anna Hospital, Geldrop; St. Elisabeth Hospital, Tilburg; TweeSteden Hospital, Tilburg; VieCurie Hospital, Venlo and Venray; and Hospital Bernhoven, Oss. This work was supported by the Jonker-Driessen Foundation and ZonMW, the Netherlands Organization for Health Research and Development and through PHAROS (Population-based HAematological Registry for Observational Studies) (#80-82500-98-01007). Dr. Lonneke van de Poll-Franse is supported by a Cancer Research Award from the Dutch Cancer Society (#UVT-2009-4349).

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital Maastricht, PO Box 5800, 6202, Maastricht, The Netherlands

    M. W. M. van der Poel & H. C. Schouten

  2. Comprehensive Cancer Centre South, Eindhoven, The Netherlands

    S. Oerlemans, F. Mols & L. V. van de Poll-Franse

  3. Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands

    S. Oerlemans, F. Mols & L. V. van de Poll-Franse

  4. Department of Internal Medicine, Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands

    J. F. M. Pruijt

  5. Department of Geriatric Medicine, TweeSteden Hospital, Tilburg, The Netherlands

    H. Maas

Authors
  1. M. W. M. van der Poel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Oerlemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. C. Schouten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Mols
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. F. M. Pruijt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Maas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. V. van de Poll-Franse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. W. M. van der Poel.

Additional information

This study has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all patients for being included in the study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Poel, M.W.M., Oerlemans, S., Schouten, H.C. et al. Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol 93, 811–819 (2014). https://doi.org/10.1007/s00277-013-1980-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1980-1

Keywords

Search

Navigation